Clinical Trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy

Dimensions: NCT03345836

Investigators

Affiliations

Organisations

  1. (1) AbbVie (United States), grid.431072.3

Sponsors/collaborators

Abstract

The objective of this study is to evaluate the efficacy and safety of upadacitinib compared to placebo as induction therapy in participants with moderately and severely active Crohn's disease (CD).

Methods

Condition: Crohn's Disease

Intervention: Oral; Tablet

Recruitment information

Gender: All

Trial period

2017-2021

Phase

Phase 3

Research Categories

Main Subject Area

Fields of Research

External sources

Access at Registry